<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758001</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI101A101</org_study_id>
    <nct_id>NCT03758001</nct_id>
  </id_info>
  <brief_title>First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors</brief_title>
  <official_title>Phase Ia/Ib Trial to Evaluate the Tolerability and Safety of IBI101 Monotherapy or in Combination With Sintilimab in Advanced Solid Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1a/1b Trial to evaluate the tolerability and safety of IBI101 monotherapy or in
      combination with Sintilimab in advanced solid tumor patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IBI101 and Sintilimab will be administered intravenously on Day 1 of every 21 days. The DLT
      observation period is 21 days starting with the first dose taken on day 1. In Phase Ia study,
      eight dose levels of IBI101 (0.01, 0.1, 0.3, 1, 3, 6, 10 and 15mg/kg) will be tested. In
      Phase Ib study, four dose levels of IBI101 (1, 3, 6 and 10mg/kg) in combination with
      Sintilimab 200mg will be tested. After dose escalation phase completed, two combination dose
      cohorts (IBI101 3mg/kg and 6mg/kg in combination with Sintilimab 200mg) will be expanded to
      10 patients each.

      IBI101 is a recombinant fully humanized IgG1 anti-tumor necrosis factor receptor superfamily
      member 4 (OX40) monoclonal antibody.

      Sintilimab is a recombinant fully humanized anti-programmed death 1 (PD1) monoclonal
      antibody.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incicende of Adverse Events (AEs)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with AE, treatment-related AE (TRAE), immune-related AEs (irAE), AE of special interest (AESI), serious adverse event (SAE), discontinuation of study drug due to AE, dose-limiting toxicity (DLT) assessed by CTCAE v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)last and AUC0-inf</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration occurred (Tmax)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residue time (MRT)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OX40 receptor occupancy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell subset analysis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody (Nab) positive rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>IBI101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI101 in combination with Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.
Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI101</intervention_name>
    <description>0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days</description>
    <arm_group_label>IBI101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI101</intervention_name>
    <description>1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days</description>
    <arm_group_label>IBI101 in combination with Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg iv infusion day 1 of every 21 days</description>
    <arm_group_label>IBI101 in combination with Sintilimab</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with locally advanced, recurrent or metastatic solid tumors who have failed
             standard treatment

          -  18 to 75 years old

          -  Life expectancy â‰¥ 12 weeks

          -  At least 1 measurable lesion

          -  ECOG PS score 0 or 1

          -  Adequate organ and bone marrow function

        Exclusion Criteria:

          -  Previous exposure to anti-OX40, anti-PD-1, anti-PD-L1, anti-PD-L2 antibody or other
             immune checkpoint inhibitors

          -  Exposure to any other investigational drug in the 4 weeks prior to 1st dose of
             investigational drug

          -  Exposure to anti-tumor agents in the 3 weeks prior to 1st dose of investigational drug

          -  Exposure to immunosuppressant in the 3 weeks prior to 1st dose of investigational drug

          -  Major surgery in the 4 weeks prior to 1st dose of investigational drug

          -  30Gy radiation in the chest in the 6 months prior to 1st dose of investigational drug

          -  History of autoimmune disease

          -  Symptomatic CNS metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinjin Chen</last_name>
    <phone>8618020293705</phone>
    <email>jinjin.chen@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu</last_name>
      <phone>86-20-87343468</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

